^
    2d
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    8d
    Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment. (PubMed, Front Pharmacol)
    In vivo, significant downregulation of p-PI3K, p-Akt, Bcl-2, and HIF1-α, and upregulation of BAX protein expression confirmed that the mechanism of action of combination therapy is related to PI3K/Akt pathway. The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer.
    Journal • PARP Biomarker • IO biomarker • Metabolomic study
    |
    BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5)
    |
    Focus V (anlotinib) • Partruvix (pamiparib)
    14d
    Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res)
    The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib) • Paishuning (senaparib)
    2ms
    A prospective, randomized, open-label, controlled clinical study comparing ivosimod combined with chemotherapy versus pamiparib combined with chemotherapy as neoadjuvant therapy for NSCLC (ChiCTR2500108304)
    P2, N=168, Recruiting, Peking University People's Hospital; Peking University People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Partruvix (pamiparib) • Anniko (penpulimab) • Yidafan (ivonescimab)
    2ms
    Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma. (PubMed, Curr Oncol)
    Treatment-emergent cytopenia was manageable and reversible with dose reductions/interruptions. Combination regimens demonstrated antitumor activity.
    P1/2 data • Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • Partruvix (pamiparib)
    4ms
    A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments. (PubMed, Front Oncol)
    After initial surgery and adjuvant imatinib, the tumor recurred. Through comprehensive analysis of gene mutation profiles (KIT and HRR gene mutations, including BRCA2), a combination therapy of fluzoparib, pamiparib, and ripretinib was administered, stabilizing the patient's condition with significant efficacy. This case highlights the importance of genetic testing and personalized targeted treatment strategies for gastrointestinal stromal tumor (GIST) patients.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • HRD (Homologous Recombination Deficiency)
    |
    KIT mutation
    |
    imatinib • Partruvix (pamiparib) • AiRuiYi (fluzoparib) • Qinlock (ripretinib)
    6ms
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    ATM mutation • PALB2 mutation • CHEK2 mutation • CHEK1 mutation
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    7ms
    BRIGHT: Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=108, Completed, Tongji Hospital | Not yet recruiting --> Completed | N=160 --> 108 | Trial completion date: Dec 2027 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Feb 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Partruvix (pamiparib)
    8ms
    BGB-290-302: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P3, N=224, Active, not recruiting, BeiGene | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    Partruvix (pamiparib)
    8ms
    Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer)
    To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
    Clinical protocol • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8)
    |
    BRCA wild-type
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Partruvix (pamiparib)
    8ms
    Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses. (PubMed, Bioorg Chem)
    Consequently, the complex structures of Fluzoparib, Pamiparib, Rucaparib, and Niraparib within PARP-2 were achieved. It suggested that the residues adjacent to Asp766 in the HD and ASL domains and the αJ-αF and ASL-αD interfaces were closely related to the selectivity and trapping mechanism. These results would provide some insights for the design and development of novel PARP-1/2 inhibitors with improved pharmacodynamic properties.
    Journal • PARP Biomarker
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    9ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=430, Enrolling by invitation, BeiGene | N=300 --> 430
    Enrollment change
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)